Julia DeVillers wants to reduce the stigma of anal cancer. “Women get it. Men get it ... It’s all directly related to getting ...

A weekly symptom-assessment intervention led by trained lay health workers may help reduce acute care use and improve ...

AbbVie’s telisotuzumab adizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this population lacking.

Hecht, MD, discusses the phase 3 OrigAMI-3 trial for patients with recurrent, unresectable, or metastatic RAS/BRAF wild-type colorectal cancer.

EVERYONE’S talking about fat jabs – the ‘miracle’ injections trimming inches off waistlines, and helping turn the tide on the ...

The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient ...

The MUHC Foundation's signature gala, Le Bal Rouge, brought together Montreal's most passionate changemakers in business, philanthropy and health care to celebrate a decade of innovation at the McGill ...

Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced that its ColoSense® test has been included in the ...

Natural antidepressants aren’t a cure-all, but science has found certain supplements may relieve symptoms—no prescription ...

Iron deficiency is more common in women than in men, and it often goes undiagnosed. Doctors share the top signs of an iron ...

Abstract Title: Phase 2 dose expansion study of DSP107, a first-in-class bi-specific 4-1BB T-cell engager, with and without atezolizumab in metastatic MSS colorectal cancer patients.

Cuts in NIH grants and the threat of more are discouraging investment and may drive trials out of the United States.